Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 38,782 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 38,782 shares of the company’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $0.54, for a total transaction of $20,942.28. Following the transaction, the director owned 2,159,860 shares in the company, valued at approximately $1,166,324.40. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Thursday, January 15th, Luke Evnin sold 37,413 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.55, for a total transaction of $20,577.15.
• On Wednesday, January 14th, Luke Evnin sold 30,616 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.57, for a total value of $17,451.12.
• On Tuesday, January 13th, Luke Evnin sold 43,198 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.55, for a total value of $23,758.90.
• On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.57, for a total value of $33,618.60.
• On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total transaction of $15,053.58.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total value of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $11,697.84.

Werewolf Therapeutics Stock Up 2.7%

Shares of NASDAQ:HOWL traded up $0.02 during mid-day trading on Tuesday, reaching $0.56. 672,657 shares of the stock were exchanged, compared to its average volume of 514,380. The stock’s 50 day simple moving average is $0.82 and its 200-day simple moving average is $1.23. Werewolf Therapeutics, Inc. has a one year low of $0.53 and a one year high of $2.38. The company has a market cap of $27.40 million, a P/E ratio of -0.35 and a beta of 0.77. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. As a group, equities research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Wall Street Analysts Forecast Growth

HOWL has been the topic of a number of recent analyst reports. Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Wedbush cut Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research note on Friday, December 19th. Bank of America reduced their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Zacks Research downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Finally, HC Wainwright cut their target price on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.75.

Institutional Trading of Werewolf Therapeutics

Several large investors have recently modified their holdings of HOWL. Bank of America Corp DE raised its stake in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares during the period. Jane Street Group LLC acquired a new position in Werewolf Therapeutics during the second quarter valued at approximately $409,000. Citadel Advisors LLC acquired a new position in shares of Werewolf Therapeutics during the 3rd quarter worth $304,000. Finally, Marshall Wace LLP bought a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth $113,000. 64.84% of the stock is owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.